ES2170503T3 - Composicion y metodo para tratar la disfuncion erectil del pene. - Google Patents

Composicion y metodo para tratar la disfuncion erectil del pene.

Info

Publication number
ES2170503T3
ES2170503T3 ES98926585T ES98926585T ES2170503T3 ES 2170503 T3 ES2170503 T3 ES 2170503T3 ES 98926585 T ES98926585 T ES 98926585T ES 98926585 T ES98926585 T ES 98926585T ES 2170503 T3 ES2170503 T3 ES 2170503T3
Authority
ES
Spain
Prior art keywords
effective
composition
mixture
amount
penis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98926585T
Other languages
English (en)
Inventor
Carlos M Samour
Scott F Krauser
Robert J Gyurik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrochem Corp
Original Assignee
Macrochem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrochem Corp filed Critical Macrochem Corp
Application granted granted Critical
Publication of ES2170503T3 publication Critical patent/ES2170503T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición para la administración tópica al pene de una persona que lo necesite, comprendiendo dicha composición (a) una cantidad farmacológicamente eficaz de prostaglandina E1; (b) una cantidad eficaz mejoradora de la penetración de un compuesto que mejora la penetración en la piel seleccionado del grupo que consiste en 1,3-dioxano, 1,3- dioxolano y acetal sustituidos con grupos hidrocarbilo de 6 a 20 átomos de carbono; (c) un portador farmacéuticamente eficaz que comprende (i) una mezcla de alcohol etílico y agua eficaz para solubilizar los componentes (a) y (b); (ii) una mezcla de alcohol isopropílico y agua eficaz para solubilizar los componentes (a) y (b); o (iii) una mezcla que comprende al menos uno de alcohol etílico y alcohol isopropílico y propilenglicol; y (d) una cantidad eficaz para el espesamiento de un agente espesante; y, opcionalmente, (e) una cantidad efectiva anti-irritante de mentol.
ES98926585T 1998-06-15 1998-06-15 Composicion y metodo para tratar la disfuncion erectil del pene. Expired - Lifetime ES2170503T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/012284 WO1999065303A1 (en) 1998-06-15 1998-06-15 Composition and method for treating penile erectile dysfunction

Publications (1)

Publication Number Publication Date
ES2170503T3 true ES2170503T3 (es) 2002-08-01

Family

ID=22267309

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98926585T Expired - Lifetime ES2170503T3 (es) 1998-06-15 1998-06-15 Composicion y metodo para tratar la disfuncion erectil del pene.

Country Status (17)

Country Link
US (1) US5942545A (es)
EP (1) EP1026947B1 (es)
JP (1) JP3513764B2 (es)
KR (1) KR20010022296A (es)
CN (1) CN1206998C (es)
AT (1) ATE209856T1 (es)
AU (1) AU764437B2 (es)
BR (1) BR9811797A (es)
CA (1) CA2296373C (es)
DE (1) DE69802838T2 (es)
DK (1) DK1026947T3 (es)
ES (1) ES2170503T3 (es)
HU (1) HU224318B1 (es)
IL (1) IL134191A0 (es)
NO (1) NO20000157L (es)
PL (1) PL189436B1 (es)
WO (1) WO1999065303A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
GR1003199B (el) 1998-08-14 1999-09-01 Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
FR2789586A1 (fr) * 1999-02-16 2000-08-18 Synthelabo Composition pharmaceutique pour administration transmucosale balanique d'alfuzosine
WO2000051978A1 (en) 1999-03-01 2000-09-08 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
ATE281432T1 (de) 1999-03-05 2004-11-15 Univ Duke C-16 ungesätigte fp-selektive prostaglandin analoge
WO2001008659A1 (en) * 1999-07-30 2001-02-08 Lakefield Minerals Ltd. Pharmaceutical compositions for topical application to treat erectile dysfunction
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6582683B2 (en) 2000-01-04 2003-06-24 Skinvisible Pharmaceuticals, Inc. Dermal barrier composition
US7105571B2 (en) * 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
KR100402334B1 (ko) * 2000-06-23 2003-10-22 환인제약 주식회사 알프로스타딜 외용제
EP1365794A2 (en) * 2000-07-21 2003-12-03 Lue, Tom Prevention and treatment of sexual arousal disorders
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
KR20030019628A (ko) * 2000-07-31 2003-03-06 오노 야꾸힝 고교 가부시키가이샤 프로스타글란딘 유도체를 유효 성분으로 하는 발기부전치료제
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
KR100649860B1 (ko) * 2000-09-01 2006-11-24 주식회사종근당 알프로스타딜 경점막 및 경피흡수제제
KR20020020536A (ko) * 2000-09-09 2002-03-15 장우영 발기유발제
KR100373540B1 (ko) * 2000-09-20 2003-02-25 최한곤 프로스타글란딘 ｅ1용 요도좌제 조성물
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
CN100581544C (zh) * 2001-03-05 2010-01-20 美国医疗产品公司 用于勃起机能障碍治疗和逆转的可注射药物组合物
CA2442448C (en) * 2001-03-30 2010-05-11 Futura Medical Developments Limited Condom with an erectogenic composition
US20030138494A1 (en) * 2001-05-15 2003-07-24 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
US6756059B2 (en) 2001-08-20 2004-06-29 Skinvisible Pharmaceuticals, Inc. Topical composition, topical composition precursor, and methods for manufacturing and using
WO2003022239A2 (en) * 2001-09-07 2003-03-20 Western Holdings Llc Stable water in oil aminophylline emulsions
KR100446960B1 (ko) * 2001-12-04 2004-09-01 김종국 프로스타글란딘 ｅ1을 포함하는 온도감응성 에멀젼 외용제조성물
KR100810404B1 (ko) * 2001-12-18 2008-03-04 환인제약 주식회사 알프로스타딜 알킬 에스테르를 함유하는 외용제 조성물
US6673841B2 (en) 2001-12-20 2004-01-06 Whan In Pharm. Co., Ltd. Alprostadil alkyl ester-containing composition for external application
MXPA04007828A (es) * 2002-02-15 2004-10-15 Nexmed Holdings Inc Composicion de prostaglandina para eltratamiento de la disfuncion erectil.
US6919348B2 (en) 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20040126339A1 (en) * 2002-12-31 2004-07-01 Roszell James A. Sunscreen composition and methods for manufacturing and using a sunscreen composition
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
EP1605913A2 (en) * 2003-03-21 2005-12-21 Nexmed (Holdings), Inc. Angiogenesis promotion by prostaglandin compositions and methods
BRPI0408454A (pt) 2003-03-21 2006-04-04 Nexmed Holdings Inc composição tópica, método de tratar a ejaculação precoce, e, uso da composição
EP1608378A1 (en) * 2003-04-02 2005-12-28 Nexmed (Holdings), Inc. Prostaglandin compositions and their use for the treatment of vasospasm
US20050049311A1 (en) * 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions
CN101829319A (zh) 2003-12-08 2010-09-15 Cpex药品公司 用于胰岛素治疗的药用组合物及方法
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20060127483A1 (en) * 2004-12-10 2006-06-15 Alan Drizen Topical drug delivery system
GEP20125432B (en) 2005-10-12 2012-03-26 Unimed Pharmaceuticals Llc Improved testosterone gel and use thereof
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
WO2008066618A2 (en) * 2006-10-20 2008-06-05 Skinvisible Pharmaceuticals, Inc. Antifungal composition and methods for using
US9005183B2 (en) * 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
US8128913B1 (en) 2007-12-06 2012-03-06 Skinvisible Pharmaceuticals, Inc. Sunscreen composition with enhanced UV-A absorber stability and methods
BRPI0800596A2 (pt) 2008-01-31 2009-09-22 Univ Minas Gerais método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer
US8299122B2 (en) * 2008-04-14 2012-10-30 Skinvisible Pharmaceuticals, Inc. Method for stabilizing retinoic acid, retinoic acid containing composition, and method of using a retinoic acid containing composition
RU2633236C2 (ru) 2011-04-07 2017-10-11 Нексмед Холдингс, Инк. Способы и композиции для лечения болезни рейно
EP4342494A3 (en) * 2019-12-09 2024-06-05 Futura Medical Developments Limited Topical composition and methods of measuring the cooling ability of a topical composition
US12472140B2 (en) 2020-02-18 2025-11-18 Ovation Science Inc. Composition and method for transdermal delivery of cannabidiol (CBD) and tetrahydrocannabinol (THC)
CA3074150C (en) 2020-02-18 2025-12-16 Ovation Science, Inc. Composition and method for transdermal delivery of cannabidiol (cbd) and delta9-tetrahydrocannabinol (thc)
CA3204479A1 (en) 2020-10-22 2022-04-28 Standard International Group Holdings, LP Transdermal treatment for erectile dysfunction

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4861764A (en) * 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
AU616571B2 (en) * 1988-10-28 1991-10-31 Shiseido Company Ltd. Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
IT1252603B (it) * 1990-04-19 1995-06-19 Giorgio Cavallini 2,4-diamino-6 piperidino pirimidina-3 ossido topico sul glande nel trattamento delle impotenze erettili
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
IT1247678B (it) * 1990-05-31 1994-12-28 Alberto Reale Metodo per la cura dell'impotenza erettiva maschile
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5399581A (en) * 1990-12-26 1995-03-21 Laragh; John H. Method and compositions for treatment of sexual impotence
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
DE69218246T2 (de) * 1991-12-23 1997-07-17 Pharmacia & Upjohn Co., Kalamazoo, Mich. Pyridylguanidine verbindungen zur behandlung von erektionsstörungen
EP0552879B1 (en) * 1992-01-21 1998-08-19 Macrochem Corporation Improved iontophoretic administration of drugs
US5400094A (en) * 1993-03-31 1995-03-21 Minnesota Mining And Manufacturing Company Condensers for overhead projectors
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5587167A (en) * 1993-09-14 1996-12-24 Choi; Hyung K. Pharmaceutical composition for prophylaxis and treatment of premature ejaculation
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment
US5451609A (en) * 1994-07-27 1995-09-19 Institut De Recherches Chimiques Et Al Treatment of impotence
US5594032A (en) * 1994-11-10 1997-01-14 Gonzalez-Cadavid; Nestor F. Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
US5620980A (en) * 1995-02-22 1997-04-15 Macrochem Corporation Method for treating hair loss
US5583144A (en) * 1995-02-24 1996-12-10 Kral; John G. Methods for treating erectile impotence
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin

Also Published As

Publication number Publication date
DK1026947T3 (da) 2002-04-02
WO1999065303A1 (en) 1999-12-23
EP1026947B1 (en) 2001-12-05
JP2000511944A (ja) 2000-09-12
AU7838798A (en) 2000-01-05
JP3513764B2 (ja) 2004-03-31
HU224318B1 (hu) 2005-07-28
CA2296373A1 (en) 1999-12-23
US5942545A (en) 1999-08-24
HUP0103346A3 (en) 2004-06-28
HUP0103346A2 (hu) 2002-01-28
CN1206998C (zh) 2005-06-22
PL189436B1 (pl) 2005-08-31
KR20010022296A (ko) 2001-03-15
AU764437B2 (en) 2003-08-21
PL338787A1 (en) 2000-11-20
ATE209856T1 (de) 2001-12-15
EP1026947A4 (en) 2000-10-25
EP1026947A1 (en) 2000-08-16
DE69802838T2 (de) 2002-06-27
HK1030133A1 (en) 2001-04-27
IL134191A0 (en) 2001-04-30
NO20000157D0 (no) 2000-01-12
CA2296373C (en) 2003-08-12
BR9811797A (pt) 2000-09-26
NO20000157L (no) 2000-02-09
DE69802838D1 (de) 2002-01-17
CN1267191A (zh) 2000-09-20

Similar Documents

Publication Publication Date Title
ES2170503T3 (es) Composicion y metodo para tratar la disfuncion erectil del pene.
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
AR021912A1 (es) Uso de apomorfina para el tratamiento de la disfuncion erectil organica en varones
AR021539A1 (es) Preparaciones topicas anhidras para la piel
MX9702699A (es) Composiciones farmaceuticas.
ES2005572A6 (es) Un procedimiento para la preparacion de nuevos derivados del tetrahidronaftaleno
EP0971705A4 (en) MEDICINE FORMULATIONS FOR HORMONE REPLACEMENT THERAPY FOR TOPICAL APPLICATION ON THE SKIN
AR030312A1 (es) Composicion novedosa para la administracion transdermica y/o transmucosica de compuestos activos, que asegura adecuados niveles terapeuticos
ES2141950T3 (es) Composiciones que contienen troxerutina complejada con fosfatidilcolina para el tratamiento topico de la impotencia erectil.
MY130857A (en) Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
PE30891A1 (es) Composiciones y metodos terapeuticos sinergicos
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
ES8308698A1 (es) Procedimiento para preparar una composicion penetrable por la piel a base de agentes terapeuticos sistematicamente activos
MXPA01003182A (es) Sistema de liberacion controlada de agentes antifungicos y queratoliticos para el tratamiento local de las infecciones fungicas de la una y los tejidos circundantes.
AR019246A1 (es) Agonistas de receptores de 5-ht1 y metoclopramida para el tratamiento de la migrana.
ES2180274T3 (es) Disoluciones nasales.
DE60112102D1 (de) Kombination aus einem no-donor und einem antioxidans zur behanndlung sexueller störungen
CO5590913A2 (es) Terapia de combinacion antivirica
EP1383540A4 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR Wounds Healing
ES2108240T3 (es) Derivados de tiosemicarbazona de 2-formilpiridina, su preparacion y su uso como agentes antitumor.
KR860000867A (ko) 급성 방사선 증후군 발현억제 및 패혈증 발현억제의 방법 및 그 조성물
ES2057054T3 (es) Preparacion farmacologica a partir de derivados de ester de la hecogenina y su aplicacion en el tratamiento de la hiperplasia benigna de prostata.
AR019327A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
AR021863A1 (es) Metodos y equipos para el tratamiento de candidiasis vulvovaginal, con nitrato de miconazol

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1026947

Country of ref document: ES